Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Free Radic Biol Med. 2010 Apr 11;49(3):307–316. doi: 10.1016/j.freeradbiomed.2010.04.004

Figure 4. Immunohistochemistry of NOS1 in liver from control, Type-1 diabetic and endotoxin-treated rats.

Figure 4

NOS1 distribution was evaluated in the perivenous area, as shown by immunohistochemistry (at 20X; shown in a red-brown color) (Villanueva et al., 2010, submitted manuscript). Arrows show the distribution of NOS1 in endothelium (black), hepatocytes (white) and Kupffer cells (grey). A rabbit NOS1 polyclonal primary antibody (from Cayman Chemical Co.) was used in the immunostaining procedure that is followed by a diaminobenzidine-based development. In control animals, NOS1 expression was visible only at the endothelium (Control). Using the same conditions in Type-1 diabetic rats, NOS1 was present in hepatocytes, endothelium and Kupffer cells. Nuclear localization of NOS1 was only seen in hepatocytes of Type-1 diabetic rats (compare cells from the three groups). In endotoxin animals (5 h after lipopolysaccharide injection), the number of NOS1-positive cells was higher than that in control animals.

HHS Vulnerability Disclosure